From Yahoo thread:
It is so exasperating.
This week's issue of Business Week magazine has a four-page article about progress reported at the SFN conference and there wasn't a word about Neotherapeutics. However, it was listed as one of 8 companies listed on page 114 under the heading "At Long Last … Hope" "Existing Alzheimer's drugs treat only the symptoms, delaying deterioration by 6 to 12 months. But new drugs in development attack the underlying cause."
Although the list has a comment about Neotrofin that "A nerve growth factor that stimulates nerve regeneration in the brain. Human clinical trials are continuing," that's it! In the other seven comments, they write things like "In advanced trials for Alzheimer's" and "Human trials expected in early 2000." Nowhere do you get the notion that Neotherapeutics is several years ahead of everyone else in the testing and approval process, as Neotherapeutics claims.
There is a side bar article titled, "How to help the brain to repair itself" but although it is about all the recent discoveries that dovetail with Neotrofin research, it is not mentioned. They write about the research published in Current Biology about how "…. the human brain can compensate for failing neural circuits - a normal side effect of aging - by calling on substitute circuits to pitch in" and no mention that this is precisely what Neotrofin produces. Later in the side bar, they write about a brain mechanism called notch signaling and how a team of neurobiologists have "figured out the notch signal, which dictates when a brain cell sends out branches that connect to other neurons can be turned on and off." Well, duh, you have been able to see that process on the Neotherapeutics website for a year now.
They also write, "If the brain could be prompted to repair itself, Alzheimer's, Parkinson's, disease, and dementia might be conquered for good." Well, if Neotherapeutics is swimming with the current and is so far out in front of everyone else, how is it that we are the only ones who know about it? I hope the PR company writes a letter to the magazine and points this all out.
|
